ICH M Multidisciplinary Guidelines: the CTD dossier, eCTD v4.0 and what actually applies

One harmonised format, five calendars: what in the ICH M series actually applies, where and from when.

In the European Union the dossier in five modules is law (Annex I to Directive 2001/83/EC); the other M guidelines are scientific guidelines, to be followed or departed from with a justification. In the United States the CTD comes in through the eCTD door. And eCTD v4.0 is a single ICH specification with different regional calendars. This guide reads the M series from M1 to M18 text by text, with version, status and jurisdiction: 27 chapters in six parts, 261 pages in the English edition, 259 in the Italian, and 17 editable tools, for €129.

This edition has been rewritten from scratch on the official sources as read on 23 September 2026. The first edition did not cover eCTD v4.0 and carried CTD section numbers that do not hold; this one has a register of 195 sources with URL and access date, and a status label on every document it cites.

The price is €129.00. Second edition, September 2026, version 2.0, with a regulatory verification cut-off of 23 September 2026: 261 pages in the English edition, 259 in the Italian, 27 chapters, 5 appendices and 17 editable tools. Buyers of the first edition receive this one at no extra cost.

Part I — The M series and its legal force (Chapters 1–4). How to read the guide, with the nine labels and five reading paths by function; the M-series calendar from 2000 to 2030; the ICH Steps and the jurisdiction rule; the inventory from M1 to M18, with the status of each text and what does not exist (M5 stopped at Step 2, there is no M17).

Part II — The CTD (Chapters 5–10). M4(R4), the organisation of the CTD and granularity; the regional Module 1 compared across the EU, the US, Japan, Canada and the UK, for format only; Module 2 with the QOS, overviews and summaries; Module 3 under M4Q(R1); Modules 4 and 5 with section numbers checked against the guidelines; M4Q(R2) as readiness, not compliance.

Part III — The eCTD (Chapters 11–14). From v3.2.2 to v4.0, with the technical differences read only from ICH and FDA sources; the five regional calendars and the decision tree for the next submission; publishing in practice: leaf titles, lifecycle, sequence planning, technical validation and QC; dossier governance, from the core dossier to cross-module consistency.

Part IV — The scientific guidelines (Chapters 15–21). M3(R2) and the timing of clinical development; the M9, M13A, M13B and M13C bioequivalence cluster, with a decision tree on which text governs; M10 for bioanalytical method validation; M12 for drug interactions; M7(R2) in brief and M14; M11 and M15; the topics in development — M16, M18, the M7 nitrosamine addendum — and how to monitor them.

Part V — The jurisdictions (Chapters 22–24). The European Union and the United Kingdom; the United States; Japan, Canada, Switzerland, Brazil and China, with the verified implementing instrument, the gaps declared where verification was not possible, and the comparative table.

Part VI — Readiness and verification (Chapters 25–27). Recurring dossier deficiencies in five families, each anchored to a text; the dossier gap assessment and the eCTD v4.0 transition plan with event-driven milestones; four case studies in the format problem → risk → decision → activities → documentation → evidence → outcome, and 25 questions an agency may ask, with expected evidence and red flags.

Plus 5 appendices. The register of 195 sources with URL and access date; the status matrix by jurisdiction; the 147 decisions, each with who decides, on what basis and where it is recorded; the cards for the 17 tools; the glossary.

Read the extract before you buy

The free extract is made of real pages from the book, not a sales summary: 20 pages in the English edition, 19 in the Italian. It contains the regulatory status box with the dates to note, the full table of contents with the real page numbers, the five eCTD calendars table from Chapter 12, a complete case study from Chapter 27 — the same method change handled in eCTD v3.2.2 in the EU and in v4.0 in the US — and the list of the 17 tools.

Who it is for. Regulatory Affairs and Regulatory Operations, eCTD publishing, Regulatory Intelligence, CMC and Module 3 authors, nonclinical and clinical authors, clinical pharmacology and generics development, QA reviewing the dossier before submission, consultants. It is written for people who prepare, publish or review a dossier and need to know which text governs a section, in which version, with what force and from when: it does not explain what a medicinal product or a marketing authorisation application is.

Who it is not for. It is not the Regulatory Affairs guide: EU authorisation procedures (centralised, MRP, DCP, national), the variations regulation, renewals, the sunset clause and assessment timelines are out of scope. It is not the ICH Q guide, nor the Q3D + M7 guide. It does not reproduce the text of the guidelines, which you should keep at hand. And it is not legal advice: its readings of legal force are interpretations based on the sources cited, not opinions.